News

BioSpace14h

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
PharmExec9h

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...
GlobalData on MSN16h

FDA approves Ionis’ donidalorsen for HAE attack prevention

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Fierce Pharma1d

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...
Managed Healthcare Executive8h

FDA Approves First in Class Therapy for Hereditary Angioedema

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

Ionis Gets FDA OK of Dawnzera in Hereditary Angioedema

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...
STAT1d

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...
TipRanks on MSN17h

Ionis Pharmaceuticals price target raised to $69 from $65 at Citi

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...
MPR1d

Dawnzera Approved to Prevent Hereditary Angioedema Attacks

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.
TipRanks on MSN18h

Ionis Pharmaceuticals price target raised to $82 from $77 at Wells Fargo

Wells Fargo analyst Yanan Zhu raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $82 from $77 and keeps an Overweight rating on the ...